Big Win for Transplant Recipients — CMS Drops Proposal That Would Have Restricted Access to Essential Drugs

The Center for Medicare & Medicaid Services (CMS) announced today a decision to drop its proposal to remove drugs from protected class status under Medicare Part D.  This means transplant recipients will continue to have access to all immunosuppressive drugs under their Medicare Part D plan.  In a letter to Representative Henry Waxman, Ranking Member of the House Energy and Commerce Committee, CMS Administrator Marilyn Tavenner stated that the agency will not move forward this year with its January proposal to remove immunosuppressive medications, antidepressants and antipsychotics from protected class status.  The letter states that the agency may revisit the issue in future years.

This is a wonderful win for the kidney community that has worked tirelessly to fight this CMS proposal.  NKF’s government relations staff has met with White House policy advisors, the Deputy Principal Administrator of CMS, and Congressional office staff to educate them about why restricting access to immunosuppressive drugs would be harmful to patients.  Thanks to the input of our transplant physician volunteers and the stories shared by many of you, we were able to make a convincing case as to why CMS should not move forward with its proposal.  Key to our success was the support of many other patient advocacy organizations, transplant associations and coalition groups who helped schedule meetings with Congressional staff and Administration staff and who attended meetings side by side to ensure that the six protected classes of medications under Medicare Part D were preserved.

Thank you to all of you for helping us achieve this important goal.  Our work is not over and we will continue to work with CMS to ensure that patients maintain this access to all immunosuppressive drugs under Medicare Part D in the future.

About these ads

About nkf _advocacy

The National Kidney Foundation's advocacy movement is for all people affected by CKD, transplant candidates and recipients, living and potential donors, donor families and caregivers. We empower, educate and encourage you to get involved on issues relating to CKD, donation and transplantation.
This entry was posted in Uncategorized. Bookmark the permalink.

6 Responses to Big Win for Transplant Recipients — CMS Drops Proposal That Would Have Restricted Access to Essential Drugs

  1. Renee Mizrahi says:

    Great news!

  2. Carmen Arnold says:

    Awesome news. Thank you very much for pressing on. I am so happy for those affected by this wonderful response of CMS.

  3. Kimberly Christian says:

    I have been following this closely. As an insured post transplant patient, this may one day affect me. A happy day for many people.

  4. Alan Philip Koelble says:

    Thank you so much…This may be a lifesaving decision for my future as a kidney transplant patient.

  5. Marsha McAfee for Kenny McAfee says:

    My husband is currently trying to appeal with his prescription drug plan – Well Care.
    He has been on Azathioprine for 33 years for his 2nd kidney transplant. The letter says they
    have denied coverage under the Medicare Part D benefit. If the (CMS) has dropped its proposal
    to remove drugs from protected class status under Medicare Part D why doesn’t the prescription
    drug plan know about this from Medicare?? This is very…..very upsetting!!!! If you could offer any assistance with this problem…..it would be greatly appreciated!

    • Hi Marsha,
      Unfortunately the protected class status for immunosuppressive drugs only applies to stand alone Part D plans and doesn’t apply to Medicare Advantage Prescription Drug Plans. I know that’s silly seeing as they are both Medicare programs. It appears Well Care is a Medicare Advantage Plan and that’s why they are able to deny the coverage if the drug is not on their formulary. I would contact your husband’s doctor to see if they can overturn the decision – most of the time this is a pretty easy process when it comes to immunosuppressive drugs, particularly if he was on the medicine previously. As a last resort there is a Medicare appeals process, which I can give you more information on, but it can be a lengthy process. Please feel free to email me at nkfadvocacy@kidney.org if you need more information.

      Thank you,
      Tonya Saffer
      Senior Federal Health Policy Director
      National Kidney Foundation

Your thoughts:

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s